President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
30 sep 2026
30 de septiembre
47%
31 de octubre
52%
30 de noviembre
50%
31 de diciembre
73%
$1,291 Vol.
30 de septiembre
$586 Vol.
47%
31 de octubre
$694 Vol.
52%
30 de noviembre
$0 Vol.
50%
31 de diciembre
$11 Vol.
73%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Mercado abierto: Aug 20, 2026, 5:43 PM ET
Volumen
$1,291Fecha de finalización
1 ene 2027Mercado abierto
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Volumen
$1,291Fecha de finalización
1 ene 2027Mercado abierto
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes